THROMBOCYTOSIS AND SYMPTOMS IN MYELOPROLIFERATIVE DISORDERS - A RETROSPECTIVE STUDY

被引：0

|

作者：

GROSSI, A

ROSSETI, S

VANNUCCHI, AM

RAFANELLI, D

FERRINI, PR

机构：

来源：

CELLULAR BLOOD COMPONENTS IN HAEMOSTASIS AND THROMBOSIS: IMPLICATIONS FROM MYELOPROLIFERATIVE DISORDERS | 1988年 / 1卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：205 / 207

页数：3

相关论文

共 50 条

[31] Platelet expression of Mpl is diminished in reactive thrombocytosis and in myeloproliferative disorders but is normal in secondary erythrocytosis.
Westwood, NB
Raj, K
Messinezy, M
Pearson, TC
BLOOD, 1999, 94 (10) : 112A - 112A
[32] PLATELET MEMBRANE GLYCOPROTEIN ABNORMALITIES IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS, ACUTE-LEUKEMIA AND SECONDARY THROMBOCYTOSIS
CLEZARDIN, P
MCGREGOR, JL
DECHAVANNE, M
CLEMETSON, KJ
THROMBOSIS AND HAEMOSTASIS, 1983, 50 (01) : 218 - 218
[33] sideroblastic refractory anemia with thrombocytosis a myeloproliferative syndrome?
Lippert, Eric
HEMATOLOGIE, 2006, 12 (06): : 369 - 370
[34] CHRONIC MYELOPROLIFERATIVE DISEASES WITH ACCOMPANYING THROMBOCYTOSIS - A CLINICOPATHOLOGICAL AND HISTOMORPHOMETRICAL STUDY ON 55 PATIENTS
THIELE, J
ZANKOVICH, R
FISCHER, R
DIEHL, V
BLUT, 1988, 57 (04): : 230 - 230
[35] MYELOPROLIFERATIVE DISORDERS - NEW INTERNATIONAL STUDY
WASSERMAN, LR
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1974, 229 (07): : 763 - 763
[36] Efficacy and Safety of Luspatercept Treatment in Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis: A Retrospective Analysis From the MEDALIST Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 7 - 8
[37] Retrospective reclassification of Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis based on the 2022 Updated International Consensus Committee: A Single Institute Study
Bridgelall, Sanjay
Pakasticali, Nagehan
Hussaini, Mohammad
Song, Jinming
Zhang, Ling
Tashkandi, Hammad
LABORATORY INVESTIGATION, 2023, 103 (03) : S1104 - S1105
[38] MORPHOLOGICAL-CHANGES OF MEGAKARYOCYTES DURING INTERFERON TREATMENT OF CHRONIC MYELOPROLIFERATIVE DISORDERS WITH EXCESSIVE THROMBOCYTOSIS (CMPDWET)
CHOTT, A
THIELE, J
GISSLINGER, H
LINKESCH, W
FRITZ, E
RADASZKIEWICZ, T
LUDWIG, H
BLUT, 1988, 57 (04): : 231 - 231
[39] WHICH TESTS ARE MOST USEFUL IN DISTINGUISHING BETWEEN REACTIVE THROMBOCYTOSIS AND THE THROMBOCYTOSIS OF MYELOPROLIFERATIVE DISEASE
RANDI, ML
FABRIS, F
ROSSI, C
GIROLAMI, A
CLINICAL AND LABORATORY HAEMATOLOGY, 1992, 14 (03): : 267 - 268
[40] WHICH TESTS ARE MOST USEFUL IN DISTINGUISHING BETWEEN REACTIVE THROMBOCYTOSIS AND THE THROMBOCYTOSIS OF MYELOPROLIFERATIVE DISEASE
MAJER, RV
DAWE, A
JONESLECOINTE, A
GREEN, PJ
CLINICAL AND LABORATORY HAEMATOLOGY, 1991, 13 (01): : 9 - 15

← 1 2 3 4 5 →